Dr. Orla Keane:

Yes, that is a risk that we foresaw in the Teagasc submission to the HPRA task force. Increased costs may result in a reluctance to treat. That certainly is a risk. While we can debate how to do it, we need to tackle the problem of antiparasitic resistance and try to slow its spread. With no drugs foreseen to come online in the short term, if the parasites develop resistance to all the drugs we have, that will present a problem. There is therefore a balance to be struck there.